Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
CBLI: Stock Quote & Summary Data
0.8%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | N/A |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 68,166 |
| Previous Close | $ 3.90 |
| 52 Wk High / Low | $ 6.35 / $ 1.15 |
| Shares Outstanding | 20,128,000 |
| Market Value | $ 77,871,206.40 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 0.61 |
| NASDAQ Official Open Price: | $ 4 |
| Date of NASDAQ Official Open Price: | Feb. 9, 2010 |
| NASDAQ Official Close Price: | $ 3.88 |
| Date of NASDAQ Official Close Price: | Feb. 8, 2010 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About CBLI?
Ask your question about about Cleveland BioLabs, Inc. (CBLI) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
CBLI was incorporated in Delaware and commenced business operations in June 2003 as a development-stage, biotechnology company, with a very specific and targeted focus on radiation drug discovery. We have devoted substantially all of our resources to the identification, development and commercialization of new types of drugs for protection of normal tissues from exposure to radiation and other stresses, such as toxic chemicals and cancer treatments. CBLI’s pipeline includes products from two primary families of compounds: protectans and curaxins. We are developing protectans as drug candidates that protect healthy tissues from acute stresses such as radiation, chemotherapy and ischemia (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents. ... More ...
Links to all Cleveland BioLabs, Inc. (CBLI) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for CBLI |
||
|
Cleveland BioLabs To Present At 12th Annual BIO CEO & Investor Conference; Webcast At 10:30 AM ET - RTT News 02/09/2010 9:36AM |
||
|
Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502 - Market Wire 01/28/2010 9:00AM |
||
|
Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference - Market Wire 01/27/2010 9:00AM |
||
|
Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502 - Market Wire 01/19/2010 1:30PM |
||
|
Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure - Market Wire 01/12/2010 9:00AM |
